Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-366-250"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"pt"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-366-250"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-366-2812
lpv:speaker	lp:Luís Paulo Alves2
lpv:spokenAs	unknown; Partido Socialista (2009-07-14--2014-06-30)3 substitute; Delegation to the EU-Turkey Joint Parliamentary Committee (2009-09-16--2014-06-30)3 member; S&D (2009-07-14--2014-06-30)3 member; REGI (2012-01-19--2014-06-30)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; Delegation to the Euro-Latin American Parliamentary Assembly (2009-09-16--2014-06-30)3 substitute; AGRI (2012-01-19--2014-06-30)3
lpv:translated text	"I am voting for this report. I consider it essential, in future, to prevent any possible mistakes existing in pharmacovigilance laws, so as to protect patients and facilitate greatly the withdrawal of dangerous medicines. This report is particularly important because the pharmacovigilance legislation in force lays down the rules on medicine safety and the monitoring thereof once they have been cleared for sale on the European market. This legislation was a great institutional step forward for Europe, regardless of one specific case that calls it into question. As such, by increasing pharmaceutical companies’ responsibilities, by requiring greater transparency and by calling for an automatic and urgent EU-level evaluation, this report serves to clarify dubious cases and will certainly contribute to achieving the goals proposed for it."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph